This video illustrates the pathogenesis of polycythemia vera (PV), a myeloproliferative neoplasm that arises from overproduction of hematopoietic stem cells in the bone marrow. The cause of PV is unknown, but may be related to a mutation in the gene coding for the Janus-associated kinase 2 (JAK2) protein. The JAK-STAT pathway helps to regulate normal blood cell production. In PV, the JAK-STAT pathway becomes overactive, leading to an increased number of red blood cells, but overproduction of white blood cells and platelets may also occur. Understanding the cellular origins of PV may lead to further insights into its clinical manifestations, including symptomatology and potential for disease progression.
Indications and Usage
Jakafi is indicated for treatment of polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyurea.
Jakafi is indicated for treatment of intermediate or high‐risk myelofibrosis (MF), including primary MF, post–polycythemia vera MF and post–essential thrombocythemia MF in adults.
Jakafi is indicated for treatment of steroid‐refractory acute graft‐versus‐host disease (GVHD) in adult and pediatric patients 12 years and older.
Important Safety Information
Please see Full Prescribing Information for Jakafi.
You are now leaving the Jakafi.com website.
You are now leaving the Jakafi.com website. This link will take you to a site that is not owned or maintained by Incyte Corporation, and Incyte is not responsible for the information contained on third party sites.